“Increased Demand for Cost-Effective and Rapid-Action Therapies”
- A significant and accelerating trend in the global generic injectables for infectious diseases market is the rising demand for affordable, fast-acting treatments to combat both routine and emergent infectious outbreaks. This trend is driven by healthcare systems prioritizing access, cost control, and preparedness in response to increasing infection rates and global health emergencies
- For instance, Cipla and Aurobindo Pharma have rapidly expanded their portfolios of injectable antibiotics and antivirals, including generic versions of remdesivir and ceftriaxone, to serve hospitals and public health procurement programs worldwide
- The ability of generic injectables to provide immediate therapeutic impact, especially in intravenous form, makes them indispensable in managing hospital-acquired infections, sepsis, and pandemics. Manufacturers are increasingly focusing on ready-to-use formulations and extended shelf-life products to meet the operational needs of healthcare providers in both developed and developing countries
- Furthermore, global regulatory support for faster approval pathways for essential generics, particularly injectables, has strengthened market access. Initiatives such as the WHO’s prequalification program and the U.S. FDA’s Drug Shortage Assistance Program have accelerated the entry of generic injectable treatments in key markets
- This trend toward rapid availability, lower costs, and growing therapeutic equivalence of injectables is shaping procurement decisions among governments, hospitals, and NGOs. As a result, companies like Hikma Pharmaceuticals and Sandoz are focusing on expanding production capacities and establishing regional supply chains to reduce dependency on single-source APIs and improve time-to-market
